Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 9/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.39 |
| ▸ | SRC | P12931 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10043745 | 0.90 | SYK (0.45) | SYKNPC1RAB9ASMN1; SMN2BACE1 | |
| SCHEMBL10072187 | 0.89 | SYK (0.47) | SYKNPC1RAB9AFGFR1SRC | |
| SCHEMBL10043679 | 0.89 | SYK (0.47) | SYKNPC1RAB9ASMN1; SMN2FGFR1 | |
| SCHEMBL10043746 | 0.86 | GRM4 (0.48) | SYKNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL10072188 | 0.86 | SYK (0.53) | SYKNPC1 | |
| SCHEMBL10043691 | 0.86 | NPC1 (0.48) | SYKNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL10043707 | 0.86 | SYK (0.43) | SYKNPC1RAB9ASMN1; SMN2FGFR1 | |
| SCHEMBL10043680 | 0.86 | SYK (0.49) | SYKNPC1RAB9ASMN1; SMN2FGFR1 | |
| SCHEMBL10043851 | 0.85 | PCTP (0.44) | SYKNPC1RAB9ASMN1; SMN2FGFR1 | |
| SCHEMBL10043705 | 0.85 | MAPT (0.54) | SYKNPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2010-04-01 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | SYK 42/4885NPC1 4095/4885RAB9A 1818/4885 |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | SYK 42/4885NPC1 4095/4885RAB9A 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.